BioTime CEO Dr. Michael West Announces the Launch of New Products and
Discusses the State of the Stem Cell Industry under the Obama
Administration at the Wisconsin Academy of Sciences, Arts, and Letters
ALAMEDA, Calif. (Business Wire EON/PRWEB ) November 19, 2008 --
BioTime, Inc. (OTCBB:BTIM)
Chief Executive Officer Michael West, Ph.D. delivered the keynote
presentation on Wednesday, November 19, at a meeting in Madison,
Wisconsin commemorating the 10th anniversary of the publication
describing the first derivation and culturing of human embryonic stem
cells. Dr. West’s presentation is titled “Opportunities and Challenges
of Commercializing Stem Cell Research.” The Wisconsin Academy, along
with University of Wisconsin-Madison and the Wisconsin Alumni Research
Foundation (WARF), hosted the two-day event titled “A Decade Celebrating
Stem Cells: Changing the Face of Medicine Ten Years Later” to
commemorate the publication of the first derivation of human embryonic
stem cells and to examine future trends.
Dr. West’s presentation included a historical overview of the
biotechnology industry, a description of historical trends in the
industry of commercializing stem cell technology, and a discussion of
future opportunities for the field. Dr. West discussed BioTime’s stem
cell research program that is focused on opportunities for near-term
revenues in the development and marketing of products derived from stem
cells.
Dr. West announced the launch of ten new cell line products and
presented data on their unique properties and potential utility in
regenerative medicine. The molecular markers of these lines are
consistent with varied types of human neural crest, mesodermal, and CNS
progenitor cells that have promise for the treatment of numerous
diseases such as cranial-facial, muscular, and neurological disorders.
Information about these cell lines will be available online at www.embryome.com
starting Monday, November 24, 2008, and the cells themselves are now
available for purchase for research purposes only through the same
website.
Lastly, Dr. West discussed federal policies relating to the industry of
regenerative medicine. He announced an open letter to President-Elect
Obama signed by 22 scientists and economists (including 19 Nobel
laureates), urging the new Administration to make regenerative medicine,
specifically, the cure of human disease, a national priority, similar in
scope to the Kennedy Administration’s commitment to land a man on the
moon within that decade. The text of the letter to President-Elect Obama
is available online at www.biotimeinc.com.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, develops blood plasma
volume expanders, blood replacement solutions for hypothermic (low
temperature) surgery, organ preservation solutions, and technology for
use in surgery, emergency trauma treatment and other applications.
BioTime's lead product Hextend is manufactured and distributed in the
U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under
exclusive licensing agreements.
BioTime has recently entered the field of regenerative medicine through
its wholly owned subsidiary Embryome
Sciences, Inc. where it plans to develop new medical and research
products using embryonic stem cell technology. Additional information
about BioTime can be found on the web at www.biotimeinc.com.
Hextend®, PentaLyte®, HetaCool®,
EmbryomicsTM, ESpyTM, and ESpanTM, are
trademarks of BioTime, Inc.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development and
potential opportunities for the company and its subsidiary, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates,”) should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
company's business, particularly those mentioned in the cautionary
statements found in the company's Securities and Exchange Commission
filings. The company disclaims any intent or obligation to update these
forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0
See the original story at: http://eon.businesswire.com/releases/stem_cell/michael_west/prweb1645174.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SW5zZS1NYWduLVpldGEtU2luZy1Mb3ZlLVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
